EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors BOTHELL, Wash., August 17, 2026 - Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments, today announced the appointment of Carol Brosgart, MD to its Board of Directors, effective August 12, 2026. Dr. Brosgart brings several decades of experience in antiviral therapy, epidemiology, and biopharma advisory. “Dr. Brosgart holds a distinguished record in antiviral drug development, having contributed to the development and FDA approval of therapies that have benefited patients worldwide,” said Roger Kornberg, Ph. D., Chairman of the Board, Chief Scientist, and Chairman of Scientific Advisory Board at Cocrystal and Nobel laureate. “Her clinical and scientific insights will be invaluable as we work to advance the clinical development of CDI-988 for norovirus, as well as the broader development of our antiviral pipeline.” James Sapirstein, Chief Executive Officer of Cocrystal Pharma added, “I’ve had the privilege o…
Open exhibit ↗Current Report · Items 7.01, 9.01 · 8-K
Cocrystal Pharma, Inc.
COCPNASDAQEQUITYCurrent
Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On August 17, 2026, Cocrystal Pharma, Inc. (the “Company”) issued a press release announcing the appointment of Carol L. Brosgart, MD to the Company’s Board of Directors. A copy of the press release is furnished as Exhibit 99.1.…
Company context
Cocrystal is a clinical-stage biotechnology company seeking to discover and develop novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. We employ unique structure-based technologies and Nobel Prize winning expertise to create antiviral drugs. These technologies are designed to efficiently deliver small molecule therapeutics that are safe, effective, and convenient to administer. We have identified promising discovery, preclinical and clinical stage antiviral compounds for unmet medical needs caused by coronavirus, influenza virus and norovirus.